Merck's IBD drug from $10.8B Prometheus deal claims its first Phase 3 win
Merck’s $10.8 billion buyout of Prometheus Biosciences is showing its first signs of paying off. The lead program of that acquisition succeeded in its first Pha...
Merck’s $10.8 billion buyout of Prometheus Biosciences is showing its first signs of paying off. The lead program of that acquisition succeeded in its first Phase 3 trial, Merck said Monday morning, beating a placebo ...